WA-ECHODYNE
Echodyne , the radar platform company, announced today the newest addition to its market-leading portfolio of radars - EchoShield. Designed from the ground-up to set a new price-performance standard for mid-range radars, EchoShield is an advanced software-defined multi-mission radar for a wide variety of commercial, defense, and government use cases.
EchoShield’s development has been informed by hundreds of customers and applications across multiple industries. The radar’s architecture builds upon the field-proven success of Echodyne’s proprietary metamaterials electronically scanned array (MESA®) radars that are in use across a wide range of applications, such as counter-UAS, border and base security, force protection, critical infrastructure security, intelligence, surveillance, and reconnaissance, UAV detect and avoid, and autonomous ground vehicles.
A pulse-Doppler cognitive 4D radar, EchoShield combines ultra-precise electronically scanned array (ESA) beamforming and real-time dynamic waveform synthesis to deliver sub-degree tracking accuracy on hundreds of objects across a broad 3D field of view. EchoShield’s cognitive search capabilities integrate onboard or offboard data stores to adapt and direct radar resources when and where required in order to deliver the right data and detail at the right time. Whether using the radar’s significant onboard processing capabilities or ingesting data-rich range-doppler spectrograms into offboard compute, EchoShield’s SDK enables deep integration and multi-sensor fusion.
EchoShield is designed to be software-optimized to mission profiles that align powerful dynamic radar resources with unique customer requirements to deliver superior radar performance. Based on market demand, the initial software release prioritizes a counter-UAS mission and excels at detecting, tracking, and classifying any uncrewed aircraft, including low slow and small drones even in dense urban environments. Further releases will match radar resources with customer demand in dozens of applications and markets.
“Radar is a fundamental sensor for a wide range of commercial and government applications, but achieving high performance at reasonable cost, size, weight and power (C-SWaP) has always been a challenge,” said Eben Frankenberg, CEO of Echodyne. “Our customers have challenged us with certain radar performance attributes and EchoShield has been designed to meet these demanding requirements. Our customers are lining up for first units and already discussing production volume, so we’re very pleased with the market reception.”
EchoShield is designed to operate in the Ku band, with radiolocation service at 15.7-16.6 GHz and radionavigation at 15.4-15.7 GHz, and is commercially exportable. Its features include:
- 130° azimuth x 90° elevation field of regard (fully customizable)
- 0.5° tracking accuracy in azimuth and elevation, with very low track splitting/dropping
- Powerful UAV classification with low false-alarms and near-zero false-negatives
- Cognitive search capabilities integrate onboard or offboard data
-
Average tracking ranges for counter-UAS mission:
- Group 1 (-20 to -10 dBsm): 2.7 to 4.8 km
- Group 2 (-10 to -5 dBsm): 4.8 to 6.4 km
- Group 3 (-5 to 5 dBsm): 6.4 to 11.4 km
“Our breakthrough Metamaterial-ESA technology unlocks a level of beamforming previously only available with large ultra-expensive AESA’s with hundreds of channels,” said Tom Driscoll, CTO of Echodyne. “EchoShield combines this precise beamforming with modern fully-adaptive cognitive-radar approaches and intelligent control software, and the result is a radar with best-in-class detection, tracking, and classification performance.”
For additional details and technical specifications, please visit our website at echodyne.com .
This device has not been authorized as required by the rules of the Federal Communications Commission. This device is not, and may not be, offered for sale or lease, or sold or leased, until authorization is obtained.
About Echodyne
Echodyne , the radar platform company, designs and delivers high-performance compact, solid-state, patent-protected MESA® radars. Ideally suited for defense, security, machine perception, and autonomy, Echodyne’s commercially priced electronically scanned array radars are used by defense and government agencies, autonomous developers, and security integrators for counter-UAS, borders and perimeter security, critical infrastructure protection, unmanned aerial vehicles, and autonomous vehicles. Privately held, the company is based in Kirkland, Washington, and is backed by Bill Gates, NEA, Madrona Venture Group, Vulcan Capital, Vanedge Capital, and Lux Capital among others. For more information, please visit: Echodyne.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom